ReviewAnnals of gastroenterological surgery2019
Recent advances of neoadjuvant chemoradiotherapy in rectal cancer: Future treatment perspectives.
Review in Annals of gastroenterological surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Can Chemoradiotherapy Expand Immune Checkpoint Blockade Responsiveness in Mismatch Repair-Proficient Rectal Cancer?Annals of gastroenterological surgery · 2026Review
- From cell counts to cellular interactions: Cu-Cyto and the co-localization index as a spatial framework for the tumor immune microenvironment of rectal cancer.International journal of clinical oncology · 2026Review
- Response Prediction of Chemoradiotherapy for Rectal Cancer Using Rapid Semi-Automated Flow Cytometry.Cancers · 2025Article
- Clinical value of fluorescence laparoscopic surgery on anastomotic leakage prevention in ultra-low rectal cancer: real-world multicenter retrospective evidence with neoadjuvant chemoradiotherapy stratification.Techniques in coloproctology · 2025Article
- Lymph node metastasis following chemoradiotherapy in advanced rectal cancer: ypT2-focused analyses of total mesorectal excision specimens.Techniques in coloproctology · 2024Article
- Anastomotic tension "Bridging": a risk factor for anastomotic leakage following low anterior resection.Surgical endoscopy · 2024Article
- Significance of ypTNM stage in determining the prognosis and therapy after surgery for locally advanced rectal cancer.World journal of surgical oncology · 2023Article
- Article
- Evaluation and Predictive Factors of Complete Response in Rectal Cancer after Neoadjuvant Chemoradiation Therapy.Medicina (Kaunas, Lithuania) · 2021Review
- Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer.British journal of cancer · 2019Article
- Article
- Recent advances of neoadjuvant chemoradiotherapy in rectal cancer: Future treatment perspectives.Annals of gastroenterological surgery · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoadjuvant chemoradiotherapy (nCRT) has been widely used as a multidisciplinary approach for stage II/III rectal cancer. However, its safety and efficacy are controversial because previous studies have shown conflicting outcomes. The present review aimed to elucidate the benefits and limitations of nCRT for patients with rectal cancer. Future perspectives of nCRT are also described. No recent randomized trials have been able to show a survival benefit, although many studies have demonstrated good local control with the use of fluoropyrimidine (e.g. 5-fluorouracil [FU] or capecitabine)-based nCRT. Addition of oxaliplatin (OX) to FU-based nCRT might improve overall survival by preventing distant metastasis, as shown in recent meta-analyses. However, control of adverse effects is an important concern with this treatment. New treatment strategies such as nonoperative management (watch and wait policy) and total neoadjuvant therapy (TNT) are promising, but the establishment of reliable diagnostic methods of metastasis is essential. Development of new biomarkers is also necessary to select patients who are more likely to benefit from nCRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.